WO2008070513A1 - Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease - Google Patents
Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease Download PDFInfo
- Publication number
- WO2008070513A1 WO2008070513A1 PCT/US2007/085847 US2007085847W WO2008070513A1 WO 2008070513 A1 WO2008070513 A1 WO 2008070513A1 US 2007085847 W US2007085847 W US 2007085847W WO 2008070513 A1 WO2008070513 A1 WO 2008070513A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ncam
- psa
- formulation
- growth factor
- eye
- Prior art date
Links
- 230000001537 neural effect Effects 0.000 title claims abstract description 9
- 108010057417 polysialyl neural cell adhesion molecule Proteins 0.000 title claims description 5
- 208000022873 Ocular disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 43
- 206010013774 Dry eye Diseases 0.000 claims abstract description 43
- 238000009472 formulation Methods 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 23
- 208000024891 symptom Diseases 0.000 claims abstract description 14
- 230000004936 stimulating effect Effects 0.000 claims abstract description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 21
- 239000003102 growth factor Substances 0.000 claims description 19
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 13
- 229940053128 nerve growth factor Drugs 0.000 claims description 12
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 10
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 10
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 claims description 10
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 8
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 8
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 5
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 5
- 239000003900 neurotrophic factor Substances 0.000 claims description 5
- 108090000742 Neurotrophin 3 Proteins 0.000 claims description 4
- 102000003683 Neurotrophin-4 Human genes 0.000 claims description 4
- 108090000099 Neurotrophin-4 Proteins 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 3
- 230000007514 neuronal growth Effects 0.000 claims description 2
- 102000013275 Somatomedins Human genes 0.000 claims 6
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 102100029268 Neurotrophin-3 Human genes 0.000 claims 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 abstract description 3
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 abstract 1
- 239000000758 substrate Substances 0.000 description 11
- 150000003904 phospholipids Chemical class 0.000 description 10
- 239000000607 artificial tear Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 102400001368 Epidermal growth factor Human genes 0.000 description 5
- 101800003838 Epidermal growth factor Proteins 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000014511 neuron projection development Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004230 Neurotrophin 3 Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940032018 neurotrophin 3 Drugs 0.000 description 3
- 229940097998 neurotrophin 4 Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- -1 such as Polymers 0.000 description 3
- 229940036266 tears naturale Drugs 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940031663 carbomer-974p Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000003838 Sialyltransferases Human genes 0.000 description 1
- 108090000141 Sialyltransferases Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 229940073464 benzododecinium bromide Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940035183 bion tears Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 229940043234 carbomer-940 Drugs 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Definitions
- This present invention relates generally to methods of treatment for dry eye.
- Dry eye also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans each year. The condition is particularly widespread among post-menopausal women due to hormonal changes following the cessation of fertility. Dry eye may afflict an individual with varying is severity. In mild cases, a patient may experience burning, a feeling of dryness, and foreign body sensation of the eyes. In severe cases, vision may be substantially impaired. Other diseases, such as Sjogren's disease, several autoimmune conditions such a rheumatoid arthritis and lupus and cicatricial pemphigoid manifest dry eye complications. Finally, trauma to the eye during surgical procedures such as lasik0 surgery or even photorefractive keratectomy may lead to dry eye symptoms.
- compositions directed to treatment of the dry eye condition have also been pursued. Many of these compositions use steroids which have limited utility due to concomitant increases in intraocular pressure and/or development of cataracts in the eye.
- embodiments of the present invention relate to a method of treating dry eye or dry eye symptoms.
- the method includes topically administering a formulation to the eye, wherein the formulation includes an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of PSA-NCAM.
- the administered formulation treats dry eye or dry eye symptoms.
- embodiments of the present invention relate to a method of stimulating the expression of PSA-NCAM in neural beds of an eye.
- the method includes topically administering a formulation to the eye.
- the formulation includes an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of PSA-NCAM.
- the administered formulation stimulates the expression of PSA-NCAM in the neural beds of the eye.
- embodiments of the present invention provide a formulation comprising an ophthalmically acceptable carrier and a therapeutically effective amount of a positive modulator of polysialic acid-neural cell adhesion molecule (PSA-NCAM).
- PSA-NCAM polysialic acid-neural cell adhesion molecule
- the present invention provides a formulation and method for the treatment of dry eye that addresses the need for repair of the neuronal bed. Such an approach may obviate the need for costly long term use of tear replacement formulations.
- Figures Ia and Ib show NCAM homophilic binding and PSA-NCAM homophilic binding, respectively. DESCRIPTION OF THE INVENTION
- a method of treating dry eye or dry eye symptoms may include topically administering a formulation to the eye.
- the formulation may include an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of polysialic acid-neural cell adhesion molecule (PSA- NCAM).
- PSA- NCAM polysialic acid-neural cell adhesion molecule
- Neural cell adhesion molecule (NCAM) and its polysialylated form (PSA- NCAM) may regulate the interactions between neuronal cells and other neighboring cells, as shown in Fig. Ia and Fig. Ib (adapted from Kiss et al. Brain Research Reviews, 2001 (36), 175-184.).
- Figure Ia shows a hypothetical homophilic binding of NCAM 100 that may stabilize cell-cell contacts through the interaction of five immunoglobulin (Ig) domains 110 within NCAM 100.
- Ig immunoglobulin
- the presence of polysialic acid (PSA) 120 on NCAM 100 may lead to reduced interactions of the Ig domains, which may reduce adhesion between neighboring cell membranes 130 and 140.
- PSA-NCAM may provide a more open environment for neurite growth facilitating branching, for example. Indeed, PSA-NCAM has been associated with neuronal plasticity and the growth of neurons. PSA-NCAM expression may be elevated during development and after a lesion (e.g. after lasik surgery). Regulation of PSA-NCAM on the cellular surface may be controlled by sialyltransferases that are responsible for the post-translational modification and by intracellular trafficking that dictates its membrane-associated residency time.
- embodiments of the present invention include treating dry eye by activating PSA-NCAM as a modulating protein for nerve bed plasticity within the cornea.
- the biosynthesis and cell surface expression of PSA-NCAM may be affected by a large number of complex cell signaling pathways, the sialyltranserferase enzymes that decorate NCAM at the Golgi apparatus, and a number of growth factors involved in neural regeneration.
- a positive modulator of PSA-NCAM is a growth factor.
- a number of growth factors may spur neuronal growth.
- a growth factor is used to stimulate expression of PSA-NCAM on the cell surface leading to enhanced neurite outgrowth.
- the positive modulator of PSA-NCAM is a growth factor such as nerve growth factor (NGF).
- NGF nerve growth factor
- TrkA protein tyrosine kinase
- PTK protein tyrosine kinase
- the positive modulator of PSA-NCAM is an epidermal growth factor (EGF).
- EGF is a growth factor that plays an important role in the regulation of cell growth, proliferation and differentiation. EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface and stimulating the intrinsic protein-tyrosine kinase activity of the receptor. The tyrosine kinase activity in turn initiates a signal transduction cascade which results in a variety of biochemical changes within the cell including a rise in intracellular calcium levels.
- EGFR epidermal growth factor receptor
- EGF as disclosed herein, encompasses natural, synthetic and recombinant forms of EGF, and may include those having deleted, replaced or altered amino acid sequences in comparison with the full- length natural EGF polypeptide or biologically active fragments thereof.
- the positive modulator of PSA-NCAM is an insulin-like growth factor (IGF), and may include, but are not limited to IGF-I and IGF-II.
- IGF-I and IGF-II as disclosed herein, encompasses natural, synthetic and recombinant forms, and may include those having deleted, replaced or altered amino acid sequences in comparison with the full-length natural polypeptide or biologically active fragments thereof.
- TGF- ⁇ transforming growth factor-alpha
- KGF keratinocyte growth factor
- PDGF-BB platelet-derived growth factors
- b-FGF basic fibroblast growth factor
- a-FGF acid fibroblast growth factor
- angiogenin and other proteins or polypeptides having mitogenic receptors relative to neural cells.
- these proteins or polypeptides encompass natural, synthetic and recombinant forms, and include those having deleted, replaced or altered amino acid sequences in comparison with the full-length natural protein or polypeptide or biologically active fragments thereof.
- the growth factors used in the present invention may be human derived.
- human derived encompasses substrates recovered from human tissues and substrates produced from human cell lines by means of recombinant DNA technology.
- aberrant PSA-NCAM is rescued by the use of a neurotrophic factor, for example brain-derived neurotrophic factor, BDNF.
- BDNF brain-derived neurotrophic factor
- BDNF may help support the survival of existing neurons, and encourage the growth and differentiation of new neurons. It has been shown that PSA-NCAM is expressed in injured brain tissue where tissue repair may benefit from reorganization and plasticity.
- the neurotrophin family (including NGF) also includes the growth factors neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Each of these may also be a positive modulator of PSA-NCAM.
- BDNF, NT-3, and NT-4 encompasses natural, synthetic and recombinant forms of these neurotrophins, and include those having deleted, replaced or altered amino acid sequences in comparison with the full-length natural neurotrophin polypeptide or biologically active fragments thereof.
- a method of treating dry eye includes topically administering to the eye a composition that comprises an ophthalmically acceptable carrier and a pharmaceutically effective amount of a modulator of PSA-NCAM.
- the pharmaceutically effective amount of the positive modulator of PSA-NCAM ranges from 2 ng/mL to 3 ⁇ g/mL.
- compositions administered may also include various other ingredients as carriers, including but not limited to surfactants, tonicity substrates, buffers, preservatives, co-solvents and viscosity building substrates.
- tonicity substrates may be employed to adjust the tonicity of the composition, preferably to that of natural tears for ophthalmic compositions.
- sodium chloride, potassium chloride, magnesium chloride, calcium chloride, dextrose and/or mannitol may be added to the composition to approximate physiological tonicity.
- Such an amount of tonicity substrate will vary, depending on the particular substrate to be added. In general, however, the compositions will have a tonicity substrate in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolarity (generally about 150-450 mOsm/L, preferably 250-350 mOsm/L).
- An appropriate buffer system e.g., sodium phosphate, sodium acetate, sodium citrate, sodium borate or boric acid
- the particular concentration will vary, depending on the substrate employed.
- the buffer will be chosen to maintain a target pH within the range of pH 6-7.5.
- compositions formulated for the treatment of dry eye-type diseases and disorders may also comprise aqueous carriers designed to provide immediate, short- term relief of dry eye-type conditions.
- aqueous carriers designed to provide immediate, short- term relief of dry eye-type conditions.
- Such carriers can be formulated as a phospholipid carrier or an artificial tears carrier, or mixtures of both.
- phospholipid carrier and artificial tears carrier refer to aqueous compositions which: (i) comprise one or more phospholipids (in the case of phospholipid carriers) or other compounds, which lubricate, "wet,” approximate the consistency of endogenous tears, aid in natural tear build-up, or otherwise provide temporary relief of dry eye symptoms and conditions upon ocular administration; and (ii) are safe.
- artificial tears compositions useful as artificial tears carriers include, but are not limited to, commercial products, such as Tears Naturale.RTM., Tears Naturale II. RTM., Tears Naturale Free. RTM., and Bion Tears. RTM. (Alcon Laboratories, Inc., Fort Worth, Tex.).
- phospholipid carrier formulations include those disclosed in U.S. Pat. Nos.
- Such compounds may enhance the viscosity of the composition, and include, but are not limited to: monomeric polyols, such as, glycerol, propylene glycol, ethylene glycol; polymeric polyols, such as, polyethylene glycol, hydroxypropylmethyl cellulose ("HPMC"), carboxy methylcellulose sodium, hydroxy propylcellulose (“HPC”), dextrans, such as, dextran 70; water soluble proteins, such as gelatin; and vinyl polymers, such as, polyvinyl alcohol, polyvinylpyrrolidone, povidone and carbomers, such as, carbomer 934P, carbomer 941, carbomer 940, carbomer 974P.
- monomeric polyols such as, glycerol, propylene glycol, ethylene glycol
- polymeric polyols such as, polyethylene glycol, hydroxypropylmethyl cellulose ("HPMC"), carboxy methylcellulose sodium, hydroxy propylcellulose (“HPC”), dex
- viscosity enhancing substrates include, but are not limited to: polysaccharides, such as hyaluronic acid and its salts, chondroitin sulfate and its salts, dextrans, various polymers of the cellulose family; carboxy vinyl polymers such as carbomers (e.g., carbomer 974P); and acrylic acid polymers.
- the phospholipid carrier or artificial tears carrier compositions will exhibit a viscosity of 1 to 400 centipoises ("cps").
- Topical ophthalmic products are typically packaged in multidose form.
- Preservatives may be beneficial to prevent microbial contamination during use. Suitable preservatives include: chlorobutanol, benzododecinium bromide, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, polyquaternium-1, or other substrates known to those skilled in the art.
- Such preservatives are typically employed at a level of from 0.001 to 1.0% w/v.
- Unit dose compositions of the present invention will be sterile, but typically unpreserved. Such compositions, therefore, generally will not contain preservatives.
- compositions of the present invention are intended for administration to a human patient suffering from dry eye or symptoms of dry eye.
- such compositions will be administered topically.
- the doses used for the above described purposes will vary, but will be in an effective amount to eliminate or improve dry eye conditions.
- 1-2 drops of such compositions will be administered from once to many times per day.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method of treating dry eye or dry eye symptom includes topically administering a formulation to the eye. The formulation includes an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of PSA-NCAM. The administered formulation treats dry eye or dry eye symptoms. A method of stimulating the expression of PSA-NCAM in neural beds of an eye includes topically administering a formulation to the eye. The formulation includes an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of PSA-NCAM. The administered formulation may stimulate the expression of PSA-NCAM in the neural beds of the eye. A formulation includes an ophthalmically acceptable carrier and a therapeutically effective amount of a positive modulator of polysialic acid-neural cell adhesion molecule (PSA-NCAM).
Description
MODULATION OF PSA-NCAM FOR THE TREATMENT OF DRY EYE
5
FIELD OF THE INVENTION
This present invention relates generally to methods of treatment for dry eye.
i o BACKGROUND OF THE INVENTION
Dry eye, also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans each year. The condition is particularly widespread among post-menopausal women due to hormonal changes following the cessation of fertility. Dry eye may afflict an individual with varying is severity. In mild cases, a patient may experience burning, a feeling of dryness, and foreign body sensation of the eyes. In severe cases, vision may be substantially impaired. Other diseases, such as Sjogren's disease, several autoimmune conditions such a rheumatoid arthritis and lupus and cicatricial pemphigoid manifest dry eye complications. Finally, trauma to the eye during surgical procedures such as lasik0 surgery or even photorefractive keratectomy may lead to dry eye symptoms.
Although it appears that dry eye may result from a number of unrelated pathogenic causes, all presentations of the complication share the common effect of the breakdown of the pre-ocular tear film, which results in damage of the exposed outer surface and many of the symptoms outlined above. 5 Practitioners have taken several approaches to the treatment of dry eye.
One common approach has been to supplement and stabilize the ocular tear film using so-called artificial tears instilled throughout the day. Other approaches include the use of ocular inserts that provide a tear substitute or stimulation of endogenous tear production.
Examples of the tear substitution approach include the use of buffered, isotonic saline solutions, aqueous solutions containing water soluble polymers that render the solutions more viscous and thus less easily shed by the eye. Tear reconstitution is also attempted by providing one or more components of the tear film such as phospholipids and oils. Phospholipid compositions have been shown to be useful in treating dry eye. Another approach involves the provision of lubricating substances in lieu of artificial tears.
Although these approaches have met with some success, problems in the treatment of dry eye nevertheless remain. The use of tear substitutes, while temporarily effective, generally requires repeated application over the course of a patient's waking hours. It is not uncommon for a patient to have to apply artificial tear solution ten to twenty times over the course of the day. Such an undertaking is not only cumbersome and time consuming, but is also potentially very expensive. Transient symptoms of dry eye associated with refractive surgery have been reported to last in some cases from six weeks to six months or more following surgery.
Aside from efforts directed primarily to the alleviation of symptoms associated with dry eye, methods and compositions directed to treatment of the dry eye condition have also been pursued. Many of these compositions use steroids which have limited utility due to concomitant increases in intraocular pressure and/or development of cataracts in the eye.
Thus, there is a continuing need for an effective pharmaceutical intervention to treat the underlying causes of dry eye. An understanding of the morphological changes associated with dry eye provides a starting point for the development of appropriate pharmaceutical treatments. Analysis of the corneas of various patient populations with dry eye or dry eye symptoms show abnormalities in neuronal beds as imaged with confocal microscopy and also show abnormalities in corneal sensitivity. The most marked change in the nerve beds is the appearance of tortuosities. A pharmaceutical formulation that may address these abnormalities in dry eye patients is, therefore, a worthwhile pursuit.
SUMMARY OF THE INVENTION
In some aspects, embodiments of the present invention relate to a method of treating dry eye or dry eye symptoms. The method includes topically administering a formulation to the eye, wherein the formulation includes an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of PSA-NCAM. The administered formulation treats dry eye or dry eye symptoms.
In other aspects, embodiments of the present invention relate to a method of stimulating the expression of PSA-NCAM in neural beds of an eye. The method includes topically administering a formulation to the eye. The formulation includes an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of PSA-NCAM. The administered formulation stimulates the expression of PSA-NCAM in the neural beds of the eye. In yet another aspect, embodiments of the present invention provide a formulation comprising an ophthalmically acceptable carrier and a therapeutically effective amount of a positive modulator of polysialic acid-neural cell adhesion molecule (PSA-NCAM).
Advantageously, the present invention provides a formulation and method for the treatment of dry eye that addresses the need for repair of the neuronal bed. Such an approach may obviate the need for costly long term use of tear replacement formulations.
BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing and other features and aspects of the present invention will be best understood with reference to the following detailed description of a specific embodiment of the invention, when read in conjunction with the accompanying drawings, wherein:
Figures Ia and Ib show NCAM homophilic binding and PSA-NCAM homophilic binding, respectively.
DESCRIPTION OF THE INVENTION
In the following description, specific details are set forth such as specific quantities, sizes, etc. so as to provide a thorough understanding of embodiments of the present invention. However, it will be obvious to those skilled in the art that the present invention may be practiced without such specific details. In many cases, details concerning such considerations and the like have been omitted inasmuch as such details are not necessary to obtain a complete understanding of the present invention and are within the skills of persons of ordinary skill in the relevant art.
Referring to the drawings in general, it will be understood that the illustrations are for the purpose of describing a particular embodiment of the invention and are not intended to limit the invention thereto.
In some embodiments, a method of treating dry eye or dry eye symptoms may include topically administering a formulation to the eye. The formulation may include an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of polysialic acid-neural cell adhesion molecule (PSA- NCAM). The administration of the formulation to the patient with dry eye with may treat the underlying cause of dry eye.
Neural cell adhesion molecule (NCAM) and its polysialylated form (PSA- NCAM) may regulate the interactions between neuronal cells and other neighboring cells, as shown in Fig. Ia and Fig. Ib (adapted from Kiss et al. Brain Research Reviews, 2001 (36), 175-184.). Figure Ia shows a hypothetical homophilic binding of NCAM 100 that may stabilize cell-cell contacts through the interaction of five immunoglobulin (Ig) domains 110 within NCAM 100. As shown in Fig. Ib, the presence of polysialic acid (PSA) 120 on NCAM 100 may lead to reduced interactions of the Ig domains, which may reduce adhesion between neighboring cell membranes 130 and 140. It has also been suggested that the presence of PSA 120 on NCAM 100 may act to alter intracellular signaling pathways. Importantly, homophilic binding with NCAM and homophilic binding with PSA-NCAM may modulate neurite outgrowth, each in a different manner. The "relaxed" cell-cell interaction associated with cells expressing surface
PSA-NCAM may provide a more open environment for neurite growth facilitating branching, for example. Indeed, PSA-NCAM has been associated with neuronal
plasticity and the growth of neurons. PSA-NCAM expression may be elevated during development and after a lesion (e.g. after lasik surgery). Regulation of PSA-NCAM on the cellular surface may be controlled by sialyltransferases that are responsible for the post-translational modification and by intracellular trafficking that dictates its membrane-associated residency time.
Thus, embodiments of the present invention include treating dry eye by activating PSA-NCAM as a modulating protein for nerve bed plasticity within the cornea. The biosynthesis and cell surface expression of PSA-NCAM may be affected by a large number of complex cell signaling pathways, the sialyltranserferase enzymes that decorate NCAM at the Golgi apparatus, and a number of growth factors involved in neural regeneration.
In some embodiments, a positive modulator of PSA-NCAM is a growth factor. A number of growth factors may spur neuronal growth. In some embodiments, a growth factor is used to stimulate expression of PSA-NCAM on the cell surface leading to enhanced neurite outgrowth.
In some embodiments, the positive modulator of PSA-NCAM is a growth factor such as nerve growth factor (NGF). NGF is known to be important for the survival and maintenance of sympathetic and sensory neurons. NGF's receptor TrkA is a protein tyrosine kinase (PTK). These kinases have been tied to cellular uptake of calcium, which in turn is associated with neurite outgrowth. NGF, as disclosed herein, encompasses natural, synthetic and recombinant forms of NGF, and may include those having deleted, replaced or altered amino acid sequences in comparison with the full-length natural NGF polypeptide or biologically active fragments thereof.
In some embodiments, the positive modulator of PSA-NCAM is an epidermal growth factor (EGF). EGF is a growth factor that plays an important role in the regulation of cell growth, proliferation and differentiation. EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface and stimulating the intrinsic protein-tyrosine kinase activity of the receptor. The tyrosine kinase activity in turn initiates a signal transduction cascade which results in a variety of biochemical changes within the cell including a rise in intracellular calcium levels.
The rise in calcium levels may induce expression of PSA-NCAM since increased calcium levels are associated with neurite outgrowth. EGF, as disclosed herein,
encompasses natural, synthetic and recombinant forms of EGF, and may include those having deleted, replaced or altered amino acid sequences in comparison with the full- length natural EGF polypeptide or biologically active fragments thereof.
In alternate embodiments, the positive modulator of PSA-NCAM is an insulin-like growth factor (IGF), and may include, but are not limited to IGF-I and IGF-II. IGF-I and IGF-II, as disclosed herein, encompasses natural, synthetic and recombinant forms, and may include those having deleted, replaced or altered amino acid sequences in comparison with the full-length natural polypeptide or biologically active fragments thereof. Other growth factors which may be utilized in the present invention include transforming growth factor-alpha (TGF-α), keratinocyte growth factor (KGF), platelet-derived growth factors (PDGF-BB, -AA, or -AB), basic fibroblast growth factor (b-FGF), acid fibroblast growth factor (a-FGF), angiogenin, and other proteins or polypeptides having mitogenic receptors relative to neural cells. As disclosed herein, these proteins or polypeptides encompass natural, synthetic and recombinant forms, and include those having deleted, replaced or altered amino acid sequences in comparison with the full-length natural protein or polypeptide or biologically active fragments thereof.
The growth factors used in the present invention may be human derived. As used herein, the term "human derived" encompasses substrates recovered from human tissues and substrates produced from human cell lines by means of recombinant DNA technology.
In yet another embodiment, aberrant PSA-NCAM is rescued by the use of a neurotrophic factor, for example brain-derived neurotrophic factor, BDNF. BDNF may help support the survival of existing neurons, and encourage the growth and differentiation of new neurons. It has been shown that PSA-NCAM is expressed in injured brain tissue where tissue repair may benefit from reorganization and plasticity. The neurotrophin family (including NGF) also includes the growth factors neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Each of these may also be a positive modulator of PSA-NCAM. BDNF, NT-3, and NT-4, as disclosed herein, encompasses natural, synthetic and recombinant forms of these neurotrophins, and include those having deleted, replaced or altered amino acid sequences in comparison
with the full-length natural neurotrophin polypeptide or biologically active fragments thereof.
In some embodiments, a method of treating dry eye includes topically administering to the eye a composition that comprises an ophthalmically acceptable carrier and a pharmaceutically effective amount of a modulator of PSA-NCAM.
In some embodiments, the pharmaceutically effective amount of the positive modulator of PSA-NCAM ranges from 2 ng/mL to 3 μg/mL.
For such topical administration, the compositions administered may also include various other ingredients as carriers, including but not limited to surfactants, tonicity substrates, buffers, preservatives, co-solvents and viscosity building substrates.
Various tonicity substrates may be employed to adjust the tonicity of the composition, preferably to that of natural tears for ophthalmic compositions. For example, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, dextrose and/or mannitol may be added to the composition to approximate physiological tonicity. Such an amount of tonicity substrate will vary, depending on the particular substrate to be added. In general, however, the compositions will have a tonicity substrate in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolarity (generally about 150-450 mOsm/L, preferably 250-350 mOsm/L).
An appropriate buffer system (e.g., sodium phosphate, sodium acetate, sodium citrate, sodium borate or boric acid) may be added to the compositions to prevent pH drift under storage conditions. The particular concentration will vary, depending on the substrate employed. Preferably, however, the buffer will be chosen to maintain a target pH within the range of pH 6-7.5.
Compositions formulated for the treatment of dry eye-type diseases and disorders may also comprise aqueous carriers designed to provide immediate, short- term relief of dry eye-type conditions. Such carriers can be formulated as a phospholipid carrier or an artificial tears carrier, or mixtures of both. As used herein, "phospholipid carrier" and "artificial tears carrier" refer to aqueous compositions which: (i) comprise one or more phospholipids (in the case of phospholipid carriers) or other compounds, which lubricate, "wet," approximate the consistency of
endogenous tears, aid in natural tear build-up, or otherwise provide temporary relief of dry eye symptoms and conditions upon ocular administration; and (ii) are safe. Examples of artificial tears compositions useful as artificial tears carriers include, but are not limited to, commercial products, such as Tears Naturale.RTM., Tears Naturale II. RTM., Tears Naturale Free. RTM., and Bion Tears. RTM. (Alcon Laboratories, Inc., Fort Worth, Tex.). Examples of phospholipid carrier formulations include those disclosed in U.S. Pat. Nos. 4,804,539 (Guo et al.), 4,883,658 (Holly), 4,914,088 (Glonek), 5,075,104 (Gressel et al.), 5,278,151 (Korb et al.), 5,294,607 (Glonek et al.), 5,371,108 (Korb et al.), 5,578,586 (Glonek et al.); the foregoing patents are incorporated herein by reference to the extent they disclose phospholipid compositions useful as phospholipid carriers of the present invention.
Other compounds designed to lubricate, "wet," approximate the consistency of endogenous tears, aid in natural tear integrity, or otherwise provide temporary relief of dry eye symptoms and conditions upon topical administration to the eye are known in the art. Such compounds may enhance the viscosity of the composition, and include, but are not limited to: monomeric polyols, such as, glycerol, propylene glycol, ethylene glycol; polymeric polyols, such as, polyethylene glycol, hydroxypropylmethyl cellulose ("HPMC"), carboxy methylcellulose sodium, hydroxy propylcellulose ("HPC"), dextrans, such as, dextran 70; water soluble proteins, such as gelatin; and vinyl polymers, such as, polyvinyl alcohol, polyvinylpyrrolidone, povidone and carbomers, such as, carbomer 934P, carbomer 941, carbomer 940, carbomer 974P.
In some embodiments, other compounds may also be added to the ophthalmic compositions to increase the viscosity or enhance the physical stability of the composition. Examples of viscosity enhancing substrates include, but are not limited to: polysaccharides, such as hyaluronic acid and its salts, chondroitin sulfate and its salts, dextrans, various polymers of the cellulose family; carboxy vinyl polymers such as carbomers (e.g., carbomer 974P); and acrylic acid polymers. In general, the phospholipid carrier or artificial tears carrier compositions will exhibit a viscosity of 1 to 400 centipoises ("cps").
Topical ophthalmic products are typically packaged in multidose form. Preservatives may be beneficial to prevent microbial contamination during use. Suitable preservatives include: chlorobutanol, benzododecinium bromide, methyl
paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, polyquaternium-1, or other substrates known to those skilled in the art. Such preservatives are typically employed at a level of from 0.001 to 1.0% w/v. Unit dose compositions of the present invention will be sterile, but typically unpreserved. Such compositions, therefore, generally will not contain preservatives.
The preferred compositions of the present invention are intended for administration to a human patient suffering from dry eye or symptoms of dry eye. Preferably, such compositions will be administered topically. In general, the doses used for the above described purposes will vary, but will be in an effective amount to eliminate or improve dry eye conditions. Generally, 1-2 drops of such compositions will be administered from once to many times per day.
All patents and publications referenced herein are hereby incorporated by reference. It will be understood that certain of the above-described structures, functions, and operations of the above-described embodiments are not necessary to practice the present invention and are included in the description simply for completeness of an exemplary embodiment or embodiments. In addition, it will be understood that specific structures, functions, and operations set forth in the above- described referenced patents and publications can be practiced in conjunction with the present invention, but they are not essential to its practice. It is therefore to be understood that the invention may be practiced otherwise than as specifically described without actually departing from the spirit and scope of the present invention as defined by the appended claims.
Claims
1. A method of treating dry eye or dry eye symptoms comprising: topically administering a formulation to the eye, the formulation comprising: an ophthalmically acceptable carrier; and a pharmaceutically effective amount of a positive modulator of PSA-
NCAM.
2. The method of claim 1, wherein the positive modulator of PSA-NCAM is a growth factor.
3. The method of claim 2, wherein the growth factor is a nerve growth factor (NGF).
4. The method of claim 2, wherein growth factor is an epidermal growth factor (EGF).
5. The method of claim 2, wherein the growth is an insulin-like growth factor (IGF).
6. The method of claim 1, wherein the modulator of PSA-NCAM is a neurotrophic factor.
7. The method of claim 6, wherein the neurotrophic factor is selected from BDNF, NT-3 and NT-4.
8. The method of claim 1, wherein the pharmaceutically effective amount of the positive modulator of PSA-NCAM is 2 ng/niL to 3 μg/mL.
9. A method of stimulating the expression of PSA-NCAM in neural beds of an eye comprising: topically administering a formulation to the eye, the formulation comprising: an ophthalmically acceptable carrier; and a pharmaceutically effective amount of a positive modulator of PSA-
NCAM.
10. The method of claim 9, wherein the positive modulator of PSA-NCAM is a growth factor.
11. The method of claim 10, wherein the growth factor is selected from the group consisting of a neural growth factor (NGF); an epidermal growth factor (EGF); and an insulin-like growth factor (IGF).
12. The method of claim 9, wherein the modulator of PSA-NCAM is a neurotrophic factor.
13. A formulation comprising an ophthalmically acceptable carrier and a therapeutically effective amount of a positive modulator of polysialic acid- neural cell adhesion molecule (PSA-NCAM).
14. The formulation of claim 13, wherein the modulator of PSA-NCAM is a growth factor.
15. The formulation of claim 14, wherein the growth factor is nerve growth factor (NGF).
16. The formulation of claim 14, wherein the growth factor is an epidermal growth factor (EGF).
17. The formulation of claim 14, wherein the growth factor receptor is an insulin- like growth factor (IGF).
18. The formulation of claim 13, wherein the modulator of PSA-NCAM is a neurotrophic factor.
19. The formulation of claim 13, wherein the pharmaceutically effective amount of the positive modulator of PSA-NCAM is 2 ng/mL to 3 μg/mL.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87341806P | 2006-12-01 | 2006-12-01 | |
US60/873,418 | 2006-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008070513A1 true WO2008070513A1 (en) | 2008-06-12 |
Family
ID=39322448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/085847 WO2008070513A1 (en) | 2006-12-01 | 2007-11-29 | Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease |
Country Status (3)
Country | Link |
---|---|
US (1) | US20080132451A1 (en) |
TW (1) | TW200831120A (en) |
WO (1) | WO2008070513A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013506410A (en) * | 2009-10-02 | 2013-02-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | DLL4 binding molecule |
JP2016026207A (en) * | 2009-10-02 | 2016-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bispecific binding molecules for anti-angiogenesis therapy |
CN106714814A (en) * | 2014-06-27 | 2017-05-24 | S生物医药公司 | Composition for treating ischemic diseases or neurogenic inflammation, containing, as active ingredient, neural progenitor cells or secretome thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995029696A1 (en) * | 1994-04-29 | 1995-11-09 | University Of Miami | Products of lacrimal gland for tear replacement |
EP0845268A2 (en) * | 1996-11-29 | 1998-06-03 | Senju Pharmaceutical Co., Ltd. | Composition for treating cornea |
WO2001030375A2 (en) * | 1999-10-29 | 2001-05-03 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Use of gdnf for treating corneal defects |
WO2002074193A2 (en) * | 2001-03-15 | 2002-09-26 | Regenerx, Biopharmaceuticals, Inc. | METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES |
WO2003005941A2 (en) * | 2001-07-12 | 2003-01-23 | Lohmann Chris P | Insert for the treatment of dry eye |
EP1734052A1 (en) * | 2005-06-13 | 2006-12-20 | Primm S.R.L. | Heterodimeric peptide compounds displaying ngf activity and their use to treat neurodegenerative disorders |
-
2007
- 2007-11-29 US US11/947,067 patent/US20080132451A1/en not_active Abandoned
- 2007-11-29 WO PCT/US2007/085847 patent/WO2008070513A1/en active Application Filing
- 2007-11-30 TW TW096145639A patent/TW200831120A/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995029696A1 (en) * | 1994-04-29 | 1995-11-09 | University Of Miami | Products of lacrimal gland for tear replacement |
EP0845268A2 (en) * | 1996-11-29 | 1998-06-03 | Senju Pharmaceutical Co., Ltd. | Composition for treating cornea |
WO2001030375A2 (en) * | 1999-10-29 | 2001-05-03 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Use of gdnf for treating corneal defects |
WO2002074193A2 (en) * | 2001-03-15 | 2002-09-26 | Regenerx, Biopharmaceuticals, Inc. | METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES |
WO2003005941A2 (en) * | 2001-07-12 | 2003-01-23 | Lohmann Chris P | Insert for the treatment of dry eye |
EP1734052A1 (en) * | 2005-06-13 | 2006-12-20 | Primm S.R.L. | Heterodimeric peptide compounds displaying ngf activity and their use to treat neurodegenerative disorders |
Non-Patent Citations (6)
Title |
---|
BONFANTI ET AL: "PSA-NCAM in mammalian structural plasticity and neurogenesis", PROGRESS IN NEUROBIOLOGY, PERGAMON PRESS, GB, vol. 80, no. 3, 16 November 2006 (2006-11-16), pages 129 - 164, XP005770896, ISSN: 0301-0082 * |
COASSIN M ET AL: "EFFICACY OF TOPICAL NERVE GROWTH FACTOR ( NGF ) TREATMENT IN DOGS AFFECTED BY DRY EYE", ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2003, 2003, & ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY; FORT LAUDERDALE, FL, USA; MAY 04-08, 2003, pages Abstract No. 2519, XP009099737 * |
GABLER B ET AL: "EGF supplement therapy with a controlled release device in patients with keratoconjunctivitis sicca seems to improve dry eye symptoms", IOVS, vol. 45, no. Suppl. 2, April 2004 (2004-04-01), & ANNUAL MEETING OF THE ASSOCIATION-FOR-RESEARCH-IN-VISION-AND-OPHTHALM OLOGY; FT LAUDERDALE, FL, USA; APRIL 24 -29, 2004, pages U333, XP009099733, ISSN: 0146-0404 * |
KISS J Z ET AL: "The role of neural cell adhesion molecules in plasticity and repair.", BRAIN RESEARCH. BRAIN RESEARCH REVIEWS OCT 2001, vol. 36, no. 2-3, October 2001 (2001-10-01), pages 175 - 184, XP009099719 * |
MARCO COASSIN ET AL: "Efficacy of topical nerve growth factor treatment in dogs affected by dry eye", GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY ; INCORPORATING GERMAN JOURNAL OF OPHTHALMOLOGY, SPRINGER-VERLAG, BE, vol. 243, no. 2, 1 February 2005 (2005-02-01), pages 151 - 155, XP019342721, ISSN: 1435-702X * |
PEPOSE J S ET AL: "Is There A Role for Neurotrophin Treatment of the Ocular Surface Following Laser In Situ Keratomileusis (LASIK)?", AMERICAN JOURNAL OF OPHTHALMOLOGY, OPHTHALMIC PUBL., CHICAGO, IL, US, vol. 139, no. 6, 1 June 2005 (2005-06-01), pages 1090 - 1094, XP004971679, ISSN: 0002-9394 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013506410A (en) * | 2009-10-02 | 2013-02-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | DLL4 binding molecule |
JP2016026207A (en) * | 2009-10-02 | 2016-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bispecific binding molecules for anti-angiogenesis therapy |
CN106714814A (en) * | 2014-06-27 | 2017-05-24 | S生物医药公司 | Composition for treating ischemic diseases or neurogenic inflammation, containing, as active ingredient, neural progenitor cells or secretome thereof |
EP3162372A4 (en) * | 2014-06-27 | 2018-06-13 | S-Biomedics | Composition for treating ischemic diseases or neurogenic inflammation, containing, as active ingredient, neural progenitor cells or secretome thereof |
EP3403658A1 (en) * | 2014-06-27 | 2018-11-21 | S-Biomedics | Composition for treating ischemic diseases or neuroinflammatory diseases containing neural progenitor cells or secretome thereof as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
TW200831120A (en) | 2008-08-01 |
US20080132451A1 (en) | 2008-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Burgalassi et al. | Development of a simple dry eye model in the albino rabbit and evaluation of some tear substitutes | |
US6063757A (en) | Wound treatment method with nerve growth factor | |
MX2007016047A (en) | Use of l-carnitine or of alkanoyl l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye-drops. | |
US5036046A (en) | Method for enhancing healing of corneal endothelial wounds | |
CN1169573C (en) | Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides | |
Yoon et al. | Therapeutic effect of umbilical cord serum eyedrops for persistent corneal epithelial defect | |
US5051443A (en) | Method for enhancing healing of corneal endothelial wounds | |
Pfister | Clinical measures to promote corneal epithelial healing | |
CN106692949B (en) | Medicine for treating eye diseases and composition thereof | |
US6537808B2 (en) | Use of nerve growth factor for the storage, culture or treatment of cornea | |
US20080132451A1 (en) | Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease | |
JPH10158171A (en) | Intraocular administrating agent formulating vitamin d compound therein | |
JP2016026229A (en) | Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use | |
Wu et al. | Chitosan-based thermosensitive hydrogel with longterm release of murine nerve growth factor for neurotrophic keratopathy | |
JP2002226395A (en) | Agent for promoting cure of skin wound | |
JPH08503968A (en) | Composition containing growth factor and antimetabolite | |
KR20150108351A (en) | Protein slurp-1 for use in the treatment of ocular diseases | |
Gillies et al. | Topical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy | |
US5032575A (en) | Method for enhancing healing of corneal endothelial wounds | |
CA2619721A1 (en) | Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease | |
RU2733392C1 (en) | Combined ophthalmic agent | |
RU2496454C2 (en) | APPLICATION OF NOVEL OLIGOPEPTIDE FRAGMENTS OF PROTEIN S100b AS STIMULATORS AND MODULATORS OF REGENERATIVE PROCESSES IN EYE CORNEA | |
CN101057823A (en) | Composite biological preparation with antisenility and beautifying function | |
Tripathi et al. | Fibroblast growth factor in the eye and prospects for its therapeutic use | |
US20210213103A1 (en) | Methods of treating dry eye syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07868938 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07868938 Country of ref document: EP Kind code of ref document: A1 |